Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
5.17
-0.06 (-1.15%)
At close: Aug 15, 2025, 1:09 PM
-1.15% (1D)
| Bid | 5.13 |
| Market Cap | 44.12M |
| Revenue (ttm) | 4.78M |
| Net Income (ttm) | -26.1M |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -2.27 |
| Forward PE | -6.31 |
| Analyst | Strong Buy |
| Ask | 5.25 |
| Volume | 2,536 |
| Avg. Volume (20D) | 84,233 |
| Open | 5.15 |
| Previous Close | 5.23 |
| Day's Range | 5.15 - 5.25 |
| 52-Week Range | 1.00 - 7.00 |
| Beta | 0.51 |
About ATHE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATHE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATHE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-14.81%
Alterity Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
3 months ago
+26.45%
Alterity Therapeutics shares are trading higher after the company announced that the FDa granted it Fast Track designation for ATH434 for the treatment of Multiple System Atrophy.
